An interventional study of CORE Plus (+) and CORE in Hypertension, sponsored by Oregon Health and Science University. Enrolling by invitation at 1 site in Nigeria. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Oregon Health and Science University · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Hypertension with a site in Nigeria — 11 open to participants now, 14 under way, none of them phase 3. Hypertension · Nigeria.
Among the 31 studies in Hypertension with a site in Nigeria, this one has the largest planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2024, is one of 17 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 23rd registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →11 of the 31 studies in Hypertension with a site in Nigeria are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in Nigeria
Ages 18+
Johns Hopkins University · Sites in Nigeria, United States, Ghana
Ages 18–70
Washington University School of Medicine · Sites in Nigeria
Women only
University of Leeds · Sites in Nigeria
Ages 18–70 · Healthy volunteers
AstraZeneca · Sites in Nigeria, Brazil, Chile and 17 more countries
Ages 18+
A study can be open while its sites in Nigeria have not opened yet or have stopped. Only those recruiting at a site in Nigeria →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24,000 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 830 across the 21 interventional studies, 2,915 across the 10 observational. Of the 14 that completed or were terminated, 3 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 31 have an industry lead sponsor. The 10 most frequent:
Oregon Health and Science University is the lead sponsor of 697 studies on the registry; 129 are open to participants now.
Of its 53 completed or terminated interventional studies of FDA-regulated products, 39 (74%) have results posted.
Oregon Health and Science University has 9 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
4 of the studies in Hypertension with a site in Nigeria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT06659900Oregon Health and Science UniversityCommunity Vital Signs (CVS): An Integrated Community-Based Approach to Identify Undiagnosed Hypertension in Nigeria | 2027-06 |
| NCT06773299Washington University School of MedicineEnhancing Intergenerational Health in Nigeria: Peripartum as Critical Life Stage for Cardiovascular Health | 2027-10 |
| NCT07386535Washington University School of MedicineInnovative Tools to Expand Music-Inspired Strategies for Blood Pressure and Stroke Prevention | 2027-10-26 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Hypertension with a site in Nigeria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
If detected early, hypertension (HTN) is treatable; yet, HTN screening rates are low and inequitable in Sub-Saharan Africa (SSA) leaving many people with undiagnosed HTN, especially in urban areas. Thus, it is a high priority to determine the acceptability, effectiveness, and sustainability of strategies to increase rates of BP screening and connections to care in SSA. The overarching goals of this project are to: 1. Adapt evidence-based implementation strategies - called community vital signs (CVS) strategies - to support BP screening and connections to care; 2. Implement the CVS strategies and assess acceptability, test their effectiveness in improving rates of BP screening and connections to care, and understand facilitators and barriers to their sustainability.
Hypertension (HTN) is a leading modifiable risk factor for global cardiovascular disease and stroke morbidity and mortality. Nigeria, Africa's most populous country, has a high HTN burden. Evidence-based interventions (EBIs) for detection and initiation of treatment for HTN are not widely implemented in Nigeria. These EBIs include widely available BP screening (reaching all adults >18 years of age) to identify HTN early and connections to ongoing primary care for HTN management. In partnership with community and clinical stakeholders, we are currently adapting community-based strategies shown to be effective in increasing HIV screening and connections to care. The proposed adapted strategies - called community vital signs (CVS) strategies - will utilize community-based screenings, digital technologies, and supportive approaches to connect people to healthcare facilities, leveraging our practice-based research network of community clinics within the Model Innovation Research Centers created by the Nigeria Implementation Science Alliance. The study team will use the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) and EPIS (Exploratory, Preparation, Implementation, Sustainment) implementation science frameworks to guide the project.
Aim 1 / R61 Phase (Year 1): Engage stakeholders to refine and finalize the co-creation of CVS strategies aiming to increase rates of BP screening and connections to care in Nigeria. By the end of the R61 Phase, the study team will have final CVS strategies and will recruit, train, and conduct implementation readiness assessments at 12 community-based sites connected with 12 healthcare facilities in 12 Nigerian cities (2 in each of Nigeria's 6 regions).
R33 Phase (Years 2-5) Aim 2: Implement and assess CVS strategies aiming to increase rates of BP screening at all 12 study sites (n=24,000 participants). The study team will initiate quarterly, community-based BP screenings and evaluate using RE-AIM.
Aim 3: Implement and compare 2 different CVS strategies to make connections to primary care for those found to have high BP readings that meet HTN criteria at all study sites. The study team will conduct a nested, hybrid implementation-effectiveness type III trial using a parallel 2-arm cluster randomized design. Arm A (6 sites, n\~3,000 participants): support connection to primary care by utilizing mHealth digital technologies with bidirectional sharing of BP data between community screening site and primary care clinic, coupled with a voucher for a medication starter kit (core strategies); Arm B (6 sites, n\~3,000 participants): Core strategies plus community health navigators making handoffs to clinic and sending text messages (core+ strategies). This project promotes equitable access to HTN diagnosis and connections to care, especially in cities where HTN prevalence is highest.
It has the potential to significantly increase rates of early HTN detection and prevent the morbidity and mortality associated with the downstream effect of undiagnosed and uncontrolled HTN. It will provide evidence for scale-up of interventions to support self-management of non-communicable chronic diseases in Nigeria and other low- and middle-income countries.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
CORE arm will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials and a voucher for a medication starter kit
Other: CORE
CORE PLUS arm will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials, a voucher for a medication starter kit PLUS support from a Community Health Advisor who will serve as a connector to primary care for HTN management and send reminder text messages.
Other: CORE Plus (+)
CORE PLUS intervention will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials, a voucher for a medication starter kit PLUS support from a Community Health Advisor who will serve as a connector to primary care for HTN management and send reminder text messages.
CORE intervention will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials and a voucher for a medication starter kit
Reach of intervention
the rate of participants who were offered BP screening by those who received BP screening
Time frame: Any point during the 24 month intervention period
Effectiveness of Intervention
Proportion of patients who were screened for HTN and met HTN threshold who were connected to care. This will be a site-level analysis using GEE models.
Time frame: Any point during the 24 month intervention period
Adoption of intervention by intervention sites
Adoption will be measured using community-observations and period reflections from the site research coordinators who conduct the intervention. The investigators will assess how well-informed community members feel about the purpose of BP screenings, the need to connect to care for ongoing HTN management, the use of tools provided by the team, and if they deviated from the study protocol to achieve the goals of the intervention.
Time frame: Any point during the 24 month intervention period
Fidelity to the Implementation of the Intervention
Longitudinal data from the Implementation Climate Measure, a survey used to assess implementation readiness, will be summarized within an across intervention sites and GEE models will be used to evaluate changes across time.
Time frame: Years 2-4
Maintenance of Intervention
Proportion of patients who were screened at baseline who return for a repeat screening. This will be assessed within and across all study sites.
Time frame: Years 2-5
Impact of intervention on diagnoses of HTN
Percent of people referred for care who get diagnosed with HTN and begin treatment on appropriate medications
Time frame: Years 2-5
Cost Effectiveness
Mean total annual costs for years 1-5, including intervention preparation and implementation by site and overall.
Time frame: Years 1-5
Impact of intervention on BP
Percent of people referred for care who have improved BP over time, measured at quarterly screening
Time frame: 12 and 24 months after enrollment
Started Jun 2024 (actual). Primary completion is estimated for Jun 2027, 36 months after the start.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 36 months is above that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oregon Health and Science University →